Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

NCT06210360 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

134

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Irinotecan liposome injection
DRUG: Oxaliplatin
DRUG: 5-FU
DRUG: LV

Sponsor

Changhai Hospital